RIGEL PHARMACEUTICALS Aktie

>RIGEL PHARMA Aktienkurs

32.4 EUR -4.1% (Tradegate)

Ask: 33.8 EUR / 50 Stück

Bid: 32.6 EUR / 60 Stück

Tagesumsatz: 677 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

RIGEL PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>RIGEL PHARMA Performance

1 Woche: -8,0%

1 Monat: +88,4%

3 Monate: +88,9%

6 Monate: +48,6%

1 Jahr: 0%

laufendes Jahr: +105,1%

>RIGEL PHARMACEUTICALS Aktie

Name:

RIGEL PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7665597024 / A40EFY

Symbol/ Ticker:

RI2 (Frankfurt) / RIGL (NASDAQ)

Kürzel:

FRA:RI2, ETR:RI2, RI2:GR, NASDAQ:RIGL

Index:

Webseite:

https://www.rigel.com/

Profil:

Rigel Pharmaceuticals Inc. is a biotechnology comp..
>Volltext..

Marktkapitalisierung:

596.36 Mio. EUR

Unternehmenswert:

556.21 Mio. EUR

Umsatz:

229.28 Mio. EUR

EBITDA:

91.58 Mio. EUR

Nettogewinn:

83.71 Mio. EUR

Gewinn je Aktie:

4.7 EUR

Schulden:

52.24 Mio. EUR

Liquide Mittel:

45.7 Mio. EUR

Operativer Cashflow:

56.33 Mio. EUR

Bargeldquote:

1.25

Umsatzwachstum:

86.96%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

RIGEL PHARMACEUTICALS, RIGEL PHARMA, RIGEL PHARMACEUTICAL

Letzte Datenerhebung:

31.08.25

>RIGEL PHARMA Kennzahlen

Aktien/ Unternehmen:

Aktien: 17.94 Mio. St.

Frei handelbar: 97.21%

Leerverk. Aktien: 11.27%

Rückkaufquote: -0.36%

Mitarbeiter: 164

Umsatz/Mitarb.: 0.94 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 2.34%

Bewertung:

KGV: 7.49

KGV lG: 7.21

KUV: 2.85

KBV: 8.87

PEG-Ratio: -

EV/EBITDA: 6.07

Rentabilität:

Bruttomarge: 91.52%

Gewinnmarge: 36.51%

Operative Marge: 39.04%

Managementeffizenz:

Gesamtkaprendite: 58.38%

Eigenkaprendite: 376.09%

>RIGEL PHARMA Peer Group

Es sind 601 Aktien bekannt.

>RIGEL PHARMA Chart & Kurs - NASDAQ

>RIGEL PHARMA News

26.08.25 - 14:09	Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean......

25.08.25 - 16:45	Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out? (Zacks)
	Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....

25.08.25 - 16:18	This ′Darling′ Pharma Stock Is Hitting New Highs (Barchart)
	Rigel Pharmaceuticals (RIGL) is showing exceptional momentum, setting new 52-week highs on Aug. 22. Shares are up nearly 243% over the past year. The stock is trading above key moving averages and is supported......

08.08.25 - 19:45	Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy? (Zacks)
	Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions....

07.08.25 - 17:30	Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
	Is it a good or bad thing when a stock experiences a golden cross technical event?...

06.08.25 - 01:45	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
	Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.08.25 - 22:09	Rigel Pharmaceuticals GAAP EPS of $3.28 beats by $1.67, revenue of $101.68M beats by $29.1M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 14:09	Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., July 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025. Rigel senior management will follow the announcement with a......

07.07.25 - 14:06	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and......

28.05.25 - 14:09	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview......

22.05.25 - 23:21	Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress (PR Newswire)
	Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals,......

07.05.25 - 05:18	Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 01:00	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
	Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.05.25 - 23:27	Rigel Pharmaceuticals Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.25 - 14:09	Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live......

04.04.25 - 14:09	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and......

27.03.25 - 15:07	Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma (AFX)
	WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc.......

27.03.25 - 13:09	Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent......

10.03.25 - 13:09	Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing......

05.03.25 - 01:00	Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
	Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Humorist lustwandelt innerhalb der Unendlichkeit. - Arthur Schnitzler

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram